These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2323818)

  • 1. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.
    Nencioni L; Pizza M; Bugnoli M; De Magistris T; Di Tommaso A; Giovannoni F; Manetti R; Marsili I; Matteucci G; Nucci D
    Infect Immun; 1990 May; 58(5):1308-15. PubMed ID: 2323818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of genetically inactivated pertussis toxin.
    Brown DR; Keith JM; Sato H; Sato Y
    Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress towards the development of new vaccines against whooping cough.
    Rappuoli R; Podda A; Pizza M; Covacci A; Bartoloni A; de Magistris MT; Nencioni L
    Vaccine; 1992; 10(14):1027-32. PubMed ID: 1471424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
    Kamachi K; Konda T; Arakawa Y
    Vaccine; 2003 Nov; 21(31):4609-15. PubMed ID: 14575775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Sato H; Sato Y
    Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis.
    Black WJ; Munoz JJ; Peacock MG; Schad PA; Cowell JL; Burchall JJ; Lim M; Kent A; Steinman L; Falkow S
    Science; 1988 Apr; 240(4852):656-9. PubMed ID: 2896387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
    Loosmore S; Zealey G; Cockle S; Boux H; Chong P; Yacoob R; Klein M
    Infect Immun; 1993 Jun; 61(6):2316-24. PubMed ID: 8500874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutants of pertussis toxin suitable for vaccine development.
    Pizza M; Covacci A; Bartoloni A; Perugini M; Nencioni L; De Magistris MT; Villa L; Nucci D; Manetti R; Bugnoli M
    Science; 1989 Oct; 246(4929):497-500. PubMed ID: 2683073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of mutant strains producing pertussis toxin cross reacting materials.
    Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
    Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
    Boucher P; Sato H; Sato Y; Locht C
    Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
    Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
    Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin.
    Zealey GR; Loosmore SM; Yacoob RK; Cockle SA; Herbert AB; Miller LD; Mackay NJ; Klein MH
    Appl Environ Microbiol; 1992 Jan; 58(1):208-14. PubMed ID: 1539974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.
    Nascimento IP; Dias WO; Mazzantini RP; Miyaji EN; Gamberini M; Quintilio W; Gebara VC; Cardoso DF; Ho PL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Infect Immun; 2000 Sep; 68(9):4877-83. PubMed ID: 10948100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
    Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
    Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
    Cropley I; Douce G; Roberts M; Chatfield S; Pizza M; Marsili I; Rappuoli R; Dougan G
    Vaccine; 1995 Dec; 13(17):1643-8. PubMed ID: 8719514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.